{
    "nctId": "NCT05946668",
    "briefTitle": "Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study",
    "officialTitle": "The VAginal Microbiome as a BiomaRker of VagInal Health in Women With BreaSt CancEr (ARISE)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Correlation of Lactobacillus to Prevotella Ratio (LPR) with vaginal dryness",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women ages 18 years and older\n* Non-metastatic, estrogen and/or progesterone positive, human epidermal growth factor (HER) 2 negative breast cancer who will be receiving endocrine therapy, including tamoxifen, aromatase inhibitor, or ovarian suppression\n* Endocrine positive women who have received chemotherapy (adriamycin and cytoxan + taxol; taxotere and cytoxan) will still be eligible but must have completed their treatment\n\nExclusion Criteria:\n\n* Triple negative breast cancer patients\n* Human epidermal growth factor (HER) 2 positive breast cancer patients\n* Metastatic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}